Indications/Uses
Listed in Dosage.
|
Dosage/Direction for Use
Adult: PO Neuropathic pain Initial: 150 mg/day, may increase up to 300 mg daily after a 3-7 days interval. Max: 600 mg/day after an additional 7 day interval. All doses to be given in 2-3 divided doses. Adjunct in partial seizures; Epilepsy Initial:150 mg/day, may increase up to 300 mg daily after 1 week. Max: 600 mg daily after an additional week. All doses to be given in 2 or 3 divided doses. Fibromyalgia Initial: 150 mg daily, may increase to 300 mg daily after 1 week. Max: 450 mg daily, if necessary. All doses to be given in 2 or 3 divided doses. Anxiety Initial: 150 mg daily, may increase in increments of 150 mg weekly. Max dose: 600 mg daily. All doses to be given in 2 or 3 divided doses.
|
Administration
May be taken with or without food.
|
Special Precautions
Patients with CV disease (including heart failure), diabetes, history of angioedema episodes or substance abuse. Elderly. Renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for signs of suicidal ideation and behaviour.
|
Adverse Reactions
Significant: Hypersensitivity, peripheral oedema, dizziness, somnolence, visual disturbance, suicidal ideation, reduced platelet count, rhabdomyolysis, creatinine kinase elevations, weight gain, PR prolongation.
Blood and lymphatic system disorders: Neutropenia.
Cardiac disorders: Tachycardia, atrioventricular block first degree, sinus bradycardia, CHF.
Ear and labyrinth disorders: Vertigo, hyperacusis.
Eye disorders: Blurred vision, diplopia, peripheral vision loss, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, photopsia, dry eye, lacrimation increased, eye irritation.
Gastrointestinal disorders: Nausea, vomiting, constipation, diarrhoea, flatulence, abdominal distention, dry mouth, GERD, salivary hypersecretion, hypoaesthesia oral.
General disorders and administration site conditions: Oedema, abnormal gait, fatigue, pyrexia, thirst, chills, asthenia.
Hepatobiliary disorders: Elevated liver enzymes.
Metabolism and nutrition disorders: Appetite increased, anorexia, hypoglycaemia.
Musculoskeletal and connective tissue disorders: Muscle cramp, arthralgia, back pain, pain in limb, cervical spasm, joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness.
Nervous system disorders: Headache, ataxia, abnormal coordination, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy.
Psychiatric disorders: Euphoric mood, confusion, irritability, disorientation, insomnia, hallucination, panic attack, restlessness, agitation, aggression, mood swings, apathy.
Renal and urinary disorders: Urinary incontinence, dysuria.
Reproductive system and breast disorders: Erectile dysfunction, sexual dysfunction, delayed ejaculation, dysmenorrhoea, breast pain.
Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, dyspnoea, epistaxis, cough, nasal congestion, rhinitis, snoring, nasal dryness.
Skin and subcutaneous tissue disorders: Rash papular, urticaria, hyperhidrosis, pruritus.
Vascular disorders: Hypotension, hypertension, flushing, peripheral coldness.
Potentially Fatal: Angioedema. |
Drug Interactions
Additive CNS depressant effects with opiates (e.g. oxycodone) and benzodiazepines (e.g. lorazepam). May increase risk of angioedema with ACE inhibitors.
|
CIMS Class
|
ATC Classification
N03AX16 - pregabalin ; Belongs to the class of other antiepileptics.
|